J&J misses quarterly revenue estimate and opens down

22 January 2020
johnson-and-johnson-hq-big

US healthcare giant Johnson & Johnson (NYSE: JNJ) opened nearly 2% lower in Wednesday’s trading after presenting its financial results for the fourth quarter of 2019, and the year as a whole.

The company reported fourth-quarter sales of $20.74 billion, up 1.7% on the same period of 2018 but below the average estimate of Wall Street experts polled by Refinitiv, who had expected $20.8 billion.

Pharma the key growth sector

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical